589 related articles for article (PubMed ID: 27073977)
1. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases.
Cacciatore I; Ciulla M; Fornasari E; Marinelli L; Di Stefano A
Expert Opin Drug Deliv; 2016 Aug; 13(8):1121-31. PubMed ID: 27073977
[TBL] [Abstract][Full Text] [Related]
2. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
[TBL] [Abstract][Full Text] [Related]
3. Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers.
Poovaiah N; Davoudi Z; Peng H; Schlichtmann B; Mallapragada S; Narasimhan B; Wang Q
Nanoscale; 2018 Sep; 10(36):16962-16983. PubMed ID: 30182106
[TBL] [Abstract][Full Text] [Related]
4. Solid lipid nanoparticles for delivery of andrographolide across the blood-brain barrier: in vitro and in vivo evaluation.
Graverini G; Piazzini V; Landucci E; Pantano D; Nardiello P; Casamenti F; Pellegrini-Giampietro DE; Bilia AR; Bergonzi MC
Colloids Surf B Biointerfaces; 2018 Jan; 161():302-313. PubMed ID: 29096375
[TBL] [Abstract][Full Text] [Related]
5. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles.
Patel M; Souto EB; Singh KK
Expert Opin Drug Deliv; 2013 Jul; 10(7):889-905. PubMed ID: 23550609
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
[TBL] [Abstract][Full Text] [Related]
7. Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery.
Battaglia L; Panciani PP; Muntoni E; Capucchio MT; Biasibetti E; De Bonis P; Mioletti S; Fontanella M; Swaminathan S
Expert Opin Drug Deliv; 2018 Apr; 15(4):369-378. PubMed ID: 29338427
[TBL] [Abstract][Full Text] [Related]
8. Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders.
Nguyen KT; Pham MN; Vo TV; Duan W; Tran PH; Tran TT
Curr Drug Metab; 2017; 18(9):786-797. PubMed ID: 28124594
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems.
Cunha S; Amaral MH; Lobo JM; Silva AC
Curr Med Chem; 2016; 23(31):3618-3631. PubMed ID: 27554805
[TBL] [Abstract][Full Text] [Related]
10. Polyphenols and Their Impact on the Prevention of Neurodegenerative Diseases and Development.
Grabska-Kobyłecka I; Szpakowski P; Król A; Książek-Winiarek D; Kobyłecki A; Głąbiński A; Nowak D
Nutrients; 2023 Aug; 15(15):. PubMed ID: 37571391
[TBL] [Abstract][Full Text] [Related]
11. Improving drug delivery technology for treating neurodegenerative diseases.
Choonara YE; Kumar P; Modi G; Pillay V
Expert Opin Drug Deliv; 2016 Jul; 13(7):1029-43. PubMed ID: 26967508
[TBL] [Abstract][Full Text] [Related]
12. Advances in the treatment of neurodegenerative disorders employing nanoparticles.
Spuch C; Saida O; Navarro C
Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):2-18. PubMed ID: 22272933
[TBL] [Abstract][Full Text] [Related]
13. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.
Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S
Nanomedicine (Lond); 2014 Apr; 9(5):709-22. PubMed ID: 24827845
[TBL] [Abstract][Full Text] [Related]
14. Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances.
Goyal K; Koul V; Singh Y; Anand A
Cent Nerv Syst Agents Med Chem; 2014; 14(1):43-59. PubMed ID: 25360772
[TBL] [Abstract][Full Text] [Related]
15. Nanobiotechnology-based drug delivery in brain targeting.
Dinda SC; Pattnaik G
Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
[TBL] [Abstract][Full Text] [Related]
16. Theranostic applications of nanoparticles in neurodegenerative disorders.
Ramanathan S; Archunan G; Sivakumar M; Tamil Selvan S; Fred AL; Kumar S; Gulyás B; Padmanabhan P
Int J Nanomedicine; 2018; 13():5561-5576. PubMed ID: 30271147
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in medicinal chemistry and pharmaceutical technology--strategies for drug delivery to the brain.
Denora N; Trapani A; Laquintana V; Lopedota A; Trapani G
Curr Top Med Chem; 2009; 9(2):182-96. PubMed ID: 19200004
[TBL] [Abstract][Full Text] [Related]
18. Research Progress of Nanocarriers for the Treatment of Alzheimer's Disease.
Li L; Zhang J; Huang X; Du J; Tu Z; Wu H; Liu X; Yuan M
Curr Pharm Des; 2023; 29(2):95-115. PubMed ID: 36529920
[TBL] [Abstract][Full Text] [Related]
19. Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region.
Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Hamano N; Li SD; Chougule M; Shoyele SA; Gupta U; Ajazuddin ; Alexander A
Expert Opin Drug Deliv; 2018 Jun; 15(6):589-617. PubMed ID: 29733231
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines.
Rajpoot K
Curr Drug Targets; 2020; 21(8):819-836. PubMed ID: 31906836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
